Terns Pharmaceuticals Stock Analysis

Terns Stock Analysis Notes

About 86.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.02. Terns Pharmaceuticals had not issued any dividends in recent years. The entity had 1000:50 split on the 4th of November 2013. Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Terns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. To find out more about Terns Pharmaceuticals contact Senthil Sundaram at 650 525 5535 or learn more at https://www.ternspharma.com.

Terns Pharmaceuticals Investment Alerts

Terns Largest EPS Surprises

View All Earnings Estimates

Terns Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Terns Pharmaceuticals Thematic Classifications

Terns Stock Institutional Investors

Note, although Terns Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Terns Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.11 B.

Terns Profitablity

Management Efficiency

Terns Pharmaceuticals has return on total asset (ROA) of (0.1994) % which means that it has lost $0.1994 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2912) %, meaning that it created substantial loss on money invested by shareholders. Terns Pharmaceuticals' management efficiency ratios could be used to measure how well Terns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 8th of February 2026, Return On Tangible Assets is likely to drop to -0.23. In addition to that, Return On Capital Employed is likely to drop to -0.28. At this time, Terns Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 8th of February 2026, Net Tangible Assets is likely to grow to about 334.4 M, while Non Current Assets Total are likely to drop about 1.5 M.

Technical Drivers

As of the 8th of February, Terns Pharmaceuticals has the Semi Deviation of 2.49, coefficient of variation of 394.73, and Risk Adjusted Performance of 0.2129. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Terns Pharmaceuticals, as well as the relationship between them.

Terns Pharmaceuticals Price Movement Analysis

Terns Pharmaceuticals Insider Trading Activities

Terns Pharmaceuticals Outstanding Bonds

Terns Pharmaceuticals Predictive Daily Indicators

Terns Pharmaceuticals Corporate Filings

Terns Pharmaceuticals Forecast Models

Terns Pharmaceuticals' time-series forecasting models are one of many Terns Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Terns Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Terns Pharmaceuticals Bond Ratings

Terns Pharmaceuticals financial ratings play a critical role in determining how much Terns Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Terns Pharmaceuticals' borrowing costs.

Terns Pharmaceuticals Debt to Cash Allocation

Terns Pharmaceuticals currently holds 1.35 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Terns Pharmaceuticals has a current ratio of 23.12, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Terns Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Terns Pharmaceuticals Total Assets Over Time

Terns Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Terns Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Terns Pharmaceuticals Debt Ratio

0.4

It appears that most of the Terns Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Terns Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Terns Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Terns Pharmaceuticals Corporate Bonds Issued

Terns Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Terns Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Terns shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Terns Pharmaceuticals. By using and applying Terns Stock analysis, traders can create a robust methodology for identifying Terns entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Terns analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Terns analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Terns Pharmaceuticals stock analysis indicators help investors evaluate how Terns Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Terns Pharmaceuticals shares will generate the highest return on investment. By understating and applying Terns Pharmaceuticals stock analysis, traders can identify Terns Pharmaceuticals position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Understanding Terns Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Terns's accounting equity. The concept of intrinsic value - what Terns Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Terns Pharmaceuticals' price substantially above or below its fundamental value.

Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Terns Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.